These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35813642)

  • 1. Insight Into Mouse Models of Hyperthyroidism.
    Zhang M; Jiang W; Lu G; Wang R; Lv Z; Li D
    Front Endocrinol (Lausanne); 2022; 13():929750. PubMed ID: 35813642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with a biologically active ICAM-1 mAb and an siRNA targeting TSHR in a BALB/c mouse model of Graves' disease.
    Wang X; Liu W; Rui Z; Zheng W; Tan J; Li N; Yu Y
    Endokrynol Pol; 2021; 72(6):592-600. PubMed ID: 34647608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cre-loxP System-Based Mouse Model for Investigating Graves' Disease and Associated Orbitopathy.
    Bao Y; Kim D; Cho YH; Ku CR; Yoon JS; Lee EJ
    Thyroid; 2023 Nov; 33(11):1358-1367. PubMed ID: 37624749
    [No Abstract]   [Full Text] [Related]  

  • 4. Mouse model of Graves' orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene.
    Wu R; Li N; Wang X; Wang S; Tan J; Wang R; Zheng W
    J Endocrinol Invest; 2024 Oct; 47(10):2507-2519. PubMed ID: 38662129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
    Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
    J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit.
    Zhang M; Ding X; Wu LP; He MQ; Chen ZY; Shi BY; Wang Y
    Thyroid; 2021 Apr; 31(4):638-648. PubMed ID: 33076782
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
    Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
    Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Early Wave of Macrophage Infiltration Intertwined with Antigen-Specific Proinflammatory T Cells and Browning of Adipose Tissue Characterizes the Onset of Orbital Inflammation in a Mouse Model of Graves' Orbitopathy.
    Philipp S; Horstmann M; Hose M; Daser A; Görtz GE; Jesenek C; Flögel U; Hansen W; Bechrakis N; Banga JPS; Eckstein A; Berchner-Pfannschmidt U
    Thyroid; 2022 Mar; 32(3):283-293. PubMed ID: 34779257
    [No Abstract]   [Full Text] [Related]  

  • 9. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy.
    Hou J; Tang Y; Chen Y; Chen D
    Front Cell Infect Microbiol; 2021; 11():739707. PubMed ID: 35004341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
    Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
    Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exceptional hyperthyroidism and a role for both major histocompatibility class I and class II genes in a murine model of Graves' disease.
    McLachlan SM; Aliesky HA; Chen CR; Williams RW; Rapoport B
    PLoS One; 2011; 6(6):e21378. PubMed ID: 21738647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.
    Moshkelgosha S; Verhasselt HL; Masetti G; Covelli D; Biscarini F; Horstmann M; Daser A; Westendorf AM; Jesenek C; Philipp S; Diaz-Cano S; Banga JP; Michael D; Plummer S; Marchesi JR; Eckstein A; Ludgate M; Berchner-Pfannschmidt U;
    Microbiome; 2021 Feb; 9(1):45. PubMed ID: 33593429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role and molecular mechanism of gut microbiota in Graves' orbitopathy.
    Li Y; Luo B; Tong B; Xie Z; Cao J; Bai X; Peng Y; Wu Y; Wang W; Qi X
    J Endocrinol Invest; 2023 Feb; 46(2):305-317. PubMed ID: 35986869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
    McLachlan SM; Rapoport B
    Thyroid; 2013 Jan; 23(1):14-24. PubMed ID: 23025526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current insights into animal models of Graves' disease and orbitopathy.
    Wiesweg B; Johnson KT; Eckstein AK; Berchner-Pfannschmidt U
    Horm Metab Res; 2013 Aug; 45(8):549-55. PubMed ID: 23613015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
    Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
    Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
    Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human placenta-derived mesenchymal stem cells ameliorate orbital adipogenesis in female mice models of Graves' ophthalmopathy.
    Park M; Banga JP; Kim GJ; Kim M; Lew H
    Stem Cell Res Ther; 2019 Aug; 10(1):246. PubMed ID: 31399042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy.
    Marcinkowski P; Hoyer I; Specker E; Furkert J; Rutz C; Neuenschwander M; Sobottka S; Sun H; Nazare M; Berchner-Pfannschmidt U; von Kries JP; Eckstein A; Schülein R; Krause G
    Thyroid; 2019 Jan; 29(1):111-123. PubMed ID: 30351237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA.
    Zhao SX; Tsui S; Cheung A; Douglas RS; Smith TJ; Banga JP
    J Endocrinol; 2011 Sep; 210(3):369-77. PubMed ID: 21715431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.